Prospects for application of phytopreparations in the complex treatment of type 2 diabetes mellitus

Authors

DOI:

https://doi.org/10.15587/2519-8025.2021.234727

Keywords:

herbal medicine, medicinal plants, type 2 diabetes mellitus

Abstract

Diabetes mellitus (DM) occupies an important place in the structure of mortality, as well as among the causes of disability and deterioration in the quality of life of the population. In this regard, the study of phytopreparations is promising for practical medicine in order to identify new medicinal plants that actively affect metabolic processes to prevent complications of DM, and create new phytopreparations. That drugs could enhance the effect of sulfonamides and potentiate the effect of insulin, thereby reducing the dose of the latter, and it is important for long-term chronic diseases, such as DM.

The aim. To study the prospects for the use of phytopreparations in the complex treatment of type 2 diabetes mellitus.

Materials and methods. The analytical, logical, generalization methods were used in the work. The analytical method of the study involved deepening the search for phytopreparations and the prospects for their use in the complex treatment of type 2 diabetes mellitus and generalization of the data obtained. The logical method of exploratory research of promising phytopreparations was applied in a certain logical sequence, as a result of which the specificity, stage-by-stage and generalization of the relevance of the use of phytopreparations in the complex treatment of type 2 diabetes mellitus was provided for scientific research. The generalizing research method was to determine and prove the characteristics of phytopreparations (analysis and synthesis) and their advantages over synthetic drugs.

Results and discussion. The main directions of herbal medicine for DM are associated with reproduction of the effects of insulin, normalization of glucose uptake, stimulation of regeneration of β-cells of the Langerhans islets, elimination of excess glucose from the body – phytopreparations with diuretic properties; elimination of hypoxia – phytopreparations-antihypoxants. In DM, herbal medicine will reduce the frequency of side effects in classical antidiabetic therapy. For any type of diabetes, herbal medicine is prescribed to patients as an improvement in the microcirculation of tissues, normalization of the functions of the cardiovascular and nervous systems, kidneys and eyes.

Conclusions. Despite a wide range of drugs used to correct the hemodynamic and metabolic manifestations of the insulin resistance syndrome, they do not fully meet the needs of practical medicine due to the presence of pronounced side effects. In addition, the pharmaceutical market of herbal medicines is very limited and represented mainly by species of medicinal plants, which have certain inconveniences in their use. All this indicates the relevance of the search, creation and introduction of effective and, at the same time, low-toxic drugs based on the medicinal plant raw material into medical practice for the pharmacotherapy of type 2 diabetes and its complications

Author Biographies

Viktoria Rybak, National University of Pharmacy

Doctor of Biological Sciences, Associate Professor

Department of Normal and Pathological Physiology

Lyudmila Maloshtan, National University of Pharmacy

Doctor of Biological Sciences, Professor

Department of Biological Chemistry

Victoria Korol, National University of Pharmacy

PhD, Associate Professor

Department of Chemistry of Natural Compounds and Nutritiology

References

  1. Shcherbak, Y. B. (2013). Vsemyrnii den dyabeta – 2013 v Ukrayne : kurs na dyabetolohycheskoe prosviashchenye y profilaktyku. Ukrainskyi medychnyi chasopys, 6 (98), 20–21.
  2. Kikhtiak, O. P. (2013). Mekhanizmy rozvytku insulinorezystentnosti ta yii misheni. Ukrainskyi medychnyi chasopys, 5 (97), 99–101.
  3. Kravchun, N. A., Chernyavskaya, I. V. (2012). Kompleksnaya terapiya mikrososudistykh oslozhneniy u patsientov s sakharnym diabetom 2-go tipa s primeneniem antitromboticheskikh preparatov. Mezhdunarodniy endokrinologicheskiy zhurnal, 5 (45), 31–35.
  4. Bharti, S. K., Krishnan, S., Kumar, A., Kumar, A. (2018). Antidiabetic phytoconstituents and their mode of action on metabolic pathways. Therapeutic Advances in Endocrinology and Metabolism, 9 (3), 81–100. doi: http://doi.org/10.1177/2042018818755019
  5. Kovalov, V. M., Kovalov, S. V., Demeshko, O. V., Dmytryievskyi, D. I., Kutsanian, A. S., Maloshtan, L. M., Rybak, V. A. (2015). Pat. No. 101843 UA. Sposib oderzhannia biolohichno aktyvnykh rechovyn z hipohlikemichnoiu diieiu. MPK A61K 36/48, A61R 3/10 (2006.01). No. a 201413120; declareted: 08.12.2014; published: 12.10.2015, Bul. No. 19, 4.
  6. Konechna, R. T., Novikov, V. P. (2008). Fitozasoby v likuvanni tsukrovoho diabetu. Visnyk Natsionalnoho universytetu «Lvivska politekhnika», 622, 64–70.
  7. Niu, C.-S., Chen, L.-J., Niu, H.-S. (2014). Antihyperglycemic action of rhodiola-aqeous extract in type1-like diabetic rats. BMC Complementary and Alternative Medicine, 14 (1). doi: http://doi.org/10.1186/1472-6882-14-20
  8. Chernykh, V. P. et. al. (2010). Suchasni aspekty peroralnoi farmakoterapii tsukrovoho diabetu 2 typu. Dosiahnennia NFaU. Kharkiv: BURUN i K, 208.
  9. Ota, A., Ulrih, N. P. (2017). An Overview of Herbal Products and Secondary Metabolites Used for Management of Type Two Diabetes. Frontiers in Pharmacology, 8. doi: http://doi.org/10.3389/fphar.2017.00436
  10. Lupak, M. I., Khokhla, M. R., Hachkova, G. Ya., Kanyuka, O. P., Klymyshyn, N. I., Chajka, Ya. P. et. al. (2015). The alkaloid-free fraction from Galega officinalis extract prevents. The Ukrainian Biochemical Journal, 8 (4), 78–86. doi: http://doi.org/10.15407/ubj87.04.078
  11. Dedov, I. I., Shestakova, M. V. (Eds.) (2015). Algoritmy spetsializirovannoy meditsinskoy pomoschi bolnym s diabetom. Moscow, 7, 1–112.
  12. Prykhodko, T. (2014). Novi alhorytmy upravlinnia tsukrovym diabetom 2 typu. Vashe zdorovia, 30-31, 22–23.
  13. Kryvoruchko, O. V., Kovalov, V. M., Kryvoruchko, V. A. (2009). Analiz lipofilnoho ekstraktu lystia kyzylu. Zhurnal orhanichnoi ta farmatsevtychnoi khimii, 7 (1 (25)), 74–76.
  14. Romanova, I. P. et. al. (2014). Do pytannia shchodo dosiahnennia kompensatsii tsukrovoho diabetu 2–ho typu. Problemy endokrynnoi patolohii, 2, 22–28.
  15. Blonde, L., Montanya, E. (2012). Comparison of liraglutide versus other incretin-related anti-hyperglycaemic agents. Diabetes, Obesity and Metabolism, 14, 20–32. doi: http://doi.org/10.1111/j.1463-1326.2012.01575.x
  16. Kalmykov, S., Kalmykova, J. (2016). The characteristics of the medicinal plants used in the herbal medicine оf type 2 diabetes. Slobozans’kij Naukovo-Sportivnij Visnik, 3 (53), 53–58. doi: http://doi.org/10.15391/snsv.2016-3.010
  17. Spiridonenko, V. V. (2014). Fitoterapiya khronicheskogo prostatita na fone metabolicheskogo sindroma i sakharnogo diabeta. Urologіya, 1, 36–41.
  18. Korpachev, V. V., Huryna, N. M., Korpacheva-Zynich, O. V. (2013). Vytamynno-myneralnii kompleks «Vytamyni dlia bolnikh dyabetom» v terapyy sakharnoho dyabeta y profylatyke eho oslonenyi. Ukrainskyi medychnyi chasopys, 2 (94), 119–123.
  19. Martynyuk, L., Martynyuk, L., Ruzhitskaya, O., Martynyuk, E. (2014). Lechebniy potentsial fitoterapii pri diabeticheskoy nefropatii u patsientov s sakharnym diabetom 2 tipa: rezultaty sravnitelnogo kogortnogo issledovaniya. Medical nature, 3, 30–37.
  20. Alekseev, I. S. (2013). Polniy atlas lekarstvennykh rasteniy. Donetsk: OOO «Gloriya Treyd», 400.
  21. Guo, J., Wang, J., Song, S., Liu, Q., Huang, Y., Xu, Y. et. al. (2016). Sphallerocarpus gracilis polysaccharide protects pancreatic β-cells via regulation of the bax/bcl-2, caspase-3, pdx-1 and insulin signalling pathways. International Journal of Biological Macromolecules, 93, 829–836. doi: http://doi.org/10.1016/j.ijbiomac.2016.08.083
  22. Pankiv, V. I. (2014). Tsukrovyi diabet 2 typu: upravliaty efektyvno, ne dopuskaiuchy pomylok. Zdorovia Ukrainy. Temat. nomer «Diabetolohiia», 1, 29–30.
  23. Samad, A., Shams, M., Ullah, Z., Wais, M., Nazish, I., Sultana, Y., Aqil, M. (2009). Status of Herbal Medicines in the Treatment of Diabetes: A Review. Current Diabetes Reviews, 5 (2), 102–111. doi: http://doi.org/10.2174/157339909788166837
  24. Chekman, I. S., Bondur, V. V., Klymenko, O. V. (2016). Kombinovana farmakoterapiia tsukrovoho diabetu 2-ho typu. Ratsionalna farmakoterapiia, 2 (39), 25–31.
  25. Pylypenko, V. M. et. al. (2010). Ratsionalna farmakoterapiia tsukrovoho diabetu 2-ho typu z vykorystanniam endohennykh rezerviv pidshlunkovoi zalozy Problemy. endokrynnoi patolohii, 1, 27–32.
  26. IDF Diabetes Atlas (2015). Brussels: International Diabetes Federation, 144. Available at: www.idf.org/diabetesatlas
  27. Kovalev, C. V., Kutsanian, A. S., Dmytryevskyi, D. Y., Sitnyk, A. H., Borodyna, N. V., Kovalev, V. N. (2008). K standartyzatsyy substantsyy y lekarstvennoi formi hlyfazyna. Zhurnal orhanichnoi ta farmatsevtychnoi khimii, 6 (2 (22)), 80–82.
  28. Kutsanian, A. S., Dmytriievskyi, D. I., Sytnyk, O. H. (2008). Rozrobka skladu ta doslidzhennia supozytoriiv z roslynnym kompleksom «Hlifazyn» dlia likuvannia diabetu. Farmatsevtychnyi chasopys, 3, 6–9.
  29. Sovtus, I. M. (2015). Possibilities of diabetes mellitus phytotherapy with medicinalplants of volyn region. Medsestrynstvo, 2, 40–43.
  30. Bletskan, M. M., Svystak, V. V. (2018). Peculiarities of phytotherapy application in obesity. Ukraina. Zdorovia natsii, 2 (49), 5–8.
  31. Derymedvid, L. V., Bukhtiiarova, I. P. (2011). Mozhlyvosti zastosuvannia kombinatsii pryrodnykh antyoksydantiv za umov pervynnoi insulinorezystentnosti. Farmakolohiia ta likarska toksykolohiia, 2 (21), 37–42.
  32. Novytska, A. V. (2016). Suchasni pidkhody do profilaktyky ta likuvannia patsiientiv z TsD 2-ho typu na rivni pervynnoi lanky nadannia medychnoi dopomohy, osoblyvosti medykamentoznoi terapii. Liky Ukrainy, 60–67.
  33. Guzyk, M. M., Dyakun, K. O., Yanitska, L. V., Kuchmerovska, Т. М. (2013). Influence of poly(ADP-ribose)polymerase inhibitors on some pa rameters of oxidative stress in blood leukocytes of rats with experimental diabetes. Украiнський біохімічний журнал, 85 (1), 62–70.
  34. Flavonoid kvertsetin – moschnoe oruzhie protiv kompleksa bolezney tsivilizatsii (2013). Prirodnaya meditsina, 1 (13), 6–9. Available at: https://health-ua.com/article/9396-flavonoid-kvertcetin-moshnoe-oruzhie-protiv-kompleksa-boleznej-tcivilizatc
  35. Rogovsky, V. S., Matyushin, A. I., Shimanovsky, N. L. (2014). The prospects of quercetinum and its derivatives administration for prevention and treatment of atherosclerosis. Prirodnaya meditsina, 2 (14), 66–69.
  36. Voloshyn, O. I., Hlubochenko, O. V., Pankiv, I. V., Holubchenko, V. H., Malkovych, N. M. (2019). Ooblyvosti fitoterapii tsukrovoho diabetu kriz pryzmu komor bidnosti y profilaktyy uskladnen (ohliad literatury). Mizhnarodnyi zhurnal endokrynolohii, 15 (3), 258–267.

Downloads

Published

2021-06-30

How to Cite

Rybak, V., Maloshtan, L., & Korol, V. (2021). Prospects for application of phytopreparations in the complex treatment of type 2 diabetes mellitus . ScienceRise: Biological Science, (2(27), 18–22. https://doi.org/10.15587/2519-8025.2021.234727

Issue

No. 2(27) (2021)

Section

Biological research

License

Copyright (c) 2021 Viktoria Rybak, Lyudmila Maloshtan, Victoria Korol

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Our journal abides by the Creative Commons CC BY copyright rights and permissions for open access journals.

Authors, who are published in this journal, agree to the following conditions:

1. The authors reserve the right to authorship of the work and pass the first publication right of this work to the journal under the terms of a Creative Commons CC BY, which allows others to freely distribute the published research with the obligatory reference to the authors of the original work and the first publication of the work in this journal.

 2. The authors have the right to conclude separate supplement agreements that relate to non-exclusive work distribution in the form in which it has been published by the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.